Diagnosis and treatment of primary glomerular diseases: Membranous nephropathy, focal segmental glomerulosclerosis and IgA nephropathy

Minerva Urologica e Nefrologica

Volumn 57, Issue 3, 2005, Pages 211-236

  Deegens, J K J ^a   Wetzels, J F M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Focal segmental glomerulosclerosis, diagnosis; Focal segmental glomerulosclerosis, therapy; IgA nephropathy, diagnosis; IgA nephropathy, therapy; Membranous nephropathy, diagnosis; Membranous nephropathy, therapy; Nephrotic syndrome, diagnosis

Indexed keywords

ALKYLATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; AZATHIOPRINE; CD20 ANTIBODY; CHLORAMBUCIL; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DOCOSAHEXAENOIC ACID; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEGA 3 FATTY ACID; PREDNISONE; RITUXIMAB; STEROID; WARFARIN;

CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; HEMATURIA; HISTORY; HUMAN; IDIOPATHIC DISEASE; IMMUNOGLOBULIN A NEPHROPATHY; INCIDENCE; KIDNEY FAILURE; MEMBRANOUS GLOMERULONEPHRITIS; META ANALYSIS; NONHUMAN; PREVALENCE; PROTEINURIA; REVIEW; SYSTEMATIC REVIEW; TONSILLECTOMY; TOXICITY; TREATMENT OUTCOME;

ANIMALS; EVIDENCE-BASED MEDICINE; GLOMERULONEPHRITIS, IGA; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; NEPHROTIC SYNDROME; TREATMENT OUTCOME;

EID: 33745419369     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (196)

1. Stengel B, Billon S, Van Dijk PC, Jager KJ, Dekker FW, Simpson K et al. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 2003;18:1824-33.
2. Van Dijk PC, Jager KJ, de Charro F, Collart F, Cornet R, Dekker FW et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001;16:1120-9.
3. van Paassen P, Breda Vriesman PJ, van Rie H, Tervaert JW. Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry. Kidney Int 2004;66:909-13.
4. Simon P, Ramee MP, Boulahrouz R, Stanescu C, Charasse C, Ang KS et al. Epidemiologic data of primary glomerular diseases in western France. Kidney Int 2004;66:905-8.
5. Vendemia F, Gesualdo L, Schena FP, D'Amico G. Epidemiology of primary glomerulonephritis in the elderly. Report from the Italian Registry of Renal Biopsy. J Nephrol 2001;14:340-52.
6. Rivera F, Lopez-Gomez JM, Perez-Garcia R. Frequency of renal pathology in Spain 1994-1999. Nephrol Dial Transplant 2002;17:1594-602.
7. Haas M, Meehan S, Karrison T, Spargo B. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997;30:621-31.
8. D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004;24:179-96.
9. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis 2000;35:157-65.
10. Kerjaschki D. Pathomechanisms and molecular basis of membranous glomerulopathy. Lancet 2004;364:1194-6.
11. Glassock RJ. Secondary membranous glomerulonephritis. Nephrol Dial Transplant 1992;7 Suppl 1:64-71.
12. Verger MF, Droz D, Vantelon J. Autoimmune thyroid diseases associated with glomerular nephropathy. 3 cases. Presse Med 1983;12:83-6.
13. Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, Bensman A et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002;346:2053-60.
14. Debiec H, Nauta J, Coulet F, van der BM, Guigonis V, Schurmans T et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 2004;364:1252-9.
15. Noel LH, Zanetti M, Droz D. Long-term prognosis of idiopathic membranous glomerulonephritis. Am J Med 1979;66:82-90.
16. Donadio JJV, Torres VE, Velosa JA, Wagoner RD, Holley KE, Okamura M et al. Idiopathic membranous nephropathy: The natural history of untreated patients. Kidney Int 1988;33:708-15.
17. McTier R, Boulton Jones JM, Payton CD, McLay A. The natural history of membranous nephropathy in the West of Scotland. Q J Med 1986;60:793-802.
18. Hay NM, Bailey RR, Lynn KL, Robson RA. Membranous nephropathy: a 19 year prospective study in 51 patients. N Z Med J 1992;105:489-91.
19. Murphy BF, Fairley KF, Kincaid-Smith PS. Idiopathic membranous glomerulonephritis: long-term follow-up in 139 cases. Clin Nephrol 1988;30:175-81.
20. Stirling CM, Simpson K, Boulton-Jones JM. Immunosuppression and outcome in idiopathic membranous nephropathy. QJM 1998;91:159-64.
21. Ohtani H, Wakui H, Komatsuda A, Okuyama S, Masai R, Maki N et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 2004;19:574-9.
22. Davison AM, Cameron JS, Kerr DN, Ogg CS, Wilkinson RW. The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin Nephrol 1984;22:61-7.
23. Cattran DC, Delmore T, Roscoe J, Cole R, Cardella C, Charron R et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. New Engl J Med 1989;320:210-5.
24. Ponticelli C, Zuchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. New Engl J Med 1989;320:8-13.
25. Collaborative study of the adult idiopathic nephrotic syndrome. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. New Engl J Med 1979;301:1301-6.
26. Honkanen E, Tornroth T, Gronhagen-Riska C, Sankila R. Long-term survival in idiopathic membranous glomerulonephritis: can the course be clinically predicted? Clin Nephrol 1994;41:127-34.
27. Durin S, Barbanel C, Landais P, Noel LH, Grunfeld JP. [Long term course of idiopathic extramembranous glomerulonephritis. Study of predictive factors of terminal renal insufficiency in 82 untreated patients]. Nephrologie 1990;11:67-71.
28. Zuchelli P, Ponticelli C, Gagnoli P, Passerini P. Long-term outcome of idiopathic membranous nephropathy with nephrotic syndrome. Nephrol Dial Transplant 1987;2:73-8.
29. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993;329:85-9.
30. Ramzy MH, Cameron JS, Turner DR, Neild GH, Ogg CS, Hicks J. The long-term outcome of idiopathic membranous nephropathy. Clin Nephrol 1981;16:13-9.
31. Cameron JS, Healy MJR, Adu D. The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. Q J Med 1990;74:133-56.
32. Ponticelli C, Zuchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48:1600-4.
33. Branten AJW, Reichert LJM, Koene RAP, Wetzels JFM. Oral cyclophosphamide versus chlorambucil in the treatment of patients with idiopathic membranous nephropathy and renal insufficiency. Q J Med 1998;91:359-66.
34. Branten AJW, Wetzels JFM. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Clin Nephrol 2001;56:1-8.
35. du Buf-Vereijken PW, Branten AJ, Wetzels JF. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol Dial Transplant 2004;19:1142-8.
36. du Buf-Vereijken PW, Feith GW, Hollander D, Gerlag PG, Wirtz JJ, Noordzij TC et al. Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort. OJM 2004;97:353-60.
37. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry Group. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004;66:1199-205.
38. Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 2004;44:385-401.
39. Torres A, Dominguez-Gil B, Carreno A, Hernandez E, Morales E, Segura J et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int 2002;61:219-27.
40. Rastogi SP, Hart-Mercer J, Kerr DN. Idiopathic membranous glomerulonephritis in adults: remission following steroid therapy. Q J Med 1969;38:335-50.
41. Hopper J Jr, Biava CG, Tu W-H. Membranous nephropathy: high dose alternate-day therapy with prednisone. West J Med 1981;135:1-8.
42. Reichert LJM, Huysmans FThM, Assmann K, Koene RAP, Wetzels JFM. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann Intern Med 1994;121:328-33.
43. Mathieson PW, Turner AN, Maidment CG, Evans DJ, Rees AJ. Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet 1988;2:869-72.
44. Bruns FJ, Adler S, Fraley DS, Segel DP. Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. Ann Intern Med 1991;114:725-30.
45. Warwick GL, Geddes CG, Boulton-Jones JM. Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure. Q J Med 1994;87:223-9.
46. Jindal K, West M, Bear R, Goldstein M. Longterm benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. Am J Kidney Dis 1992;19:61-7.
47. Brunkhorst R, Wrenger E, Koch KM. Low-dose prednisolone/chlorambucil therapy in patients with severe membranous glomerulonephritis. Clin Invest 1994;72:277-82.
48. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998;9:444-50.
49. Wetzels JF, Reichert LJ. Efficacy of immunosuppressive treatment in patients with membranous nephropathy and renal insufficiency. Kidney Int Suppl 1997;61: S63-6.
50. Bone JM, Rustom R, Williams PS. 'Progressive' versus 'indolent' idiopathic membranous glomerulonephritis. QJM 1997;90:699-706.
51. Williams PS, Bone JM. Immunosuppression can arrest progressive renal failure due to idiopathic membranous glomerulonephritis. Nephrol DialysisTransplant 1989;4:181-6.
52. Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998;31:213-7.
53. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002;61:1098-114.
54. Miller G, Zimmerman R 3rd, Radhakrishnan J, Appel G. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000;36:250-6.
55. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 2002;360:923-4.
56. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003;14:1851-7.
57. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 1995;47:1130-5.
58. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001;59:1484-90.
59. Reichert LJM, Koene RAP, Wetzels JFM. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis 1998;31:1-11.
60. Pei Y, Cattran DC, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1992;42:960-6.
61. Cattran DC, Pei Y, Greenwood CMT, Ponticelli C, Passerini P, Honkanen E. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997;51:901-7.
62. Bazzi C, Petrini C, Rizza V, Arrigo G, Beltrame A, Pisano L et al. Urinary excretion of IgG and alpha (1) microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Am J Kidney Dis 2001;38:240-8.
63. Bazzi C, D'Amico G. The urinary excretion of IgG and alpha 1-microglobulin predicts renal outcome and identifies patients deserving treatment in membranous nephropathy. Kidney Int 2002;61:2276.
64. Reichert LJM, Koene RAP, Wetzels JFM. Urinary excretion of β2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. J Am Soc Nephrol 1995;6:1666-9.
65. Reichert IJM, Koene RAP, Wetzels JFM. Urinary IgG excretion as a prognostic factor in idiopathic membranous nephropathy. Clin Nephrol 1997;48:79-84.
66. Branten AJ, du Buf-Vereijken PW, Klasen IS, Bosch FH, Feith GW, Hollander DA et al. Urinary excretion of β2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy. A validation study. J Am Soc Nephrol 2005;16:169-74.
67. Rich AR. A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis. Bull Johns Hopkins Hosp 1957;100:173-86.
68. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998;54:687-97.
69. D'Agati V, Fogo A, Bruijn J, Jennette J. Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am J Kidney Dis 2004;43:368-82.
70. Tryggvason K. Unraveling the mechanism of glomerular ultrafiltration; nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 1999;10:2440-5.
71. Lowik MM, Hol FA, Steenbergen EJ, Wetzels JF, van den Heuvel LP. Mitochondrial tRNALeu(UUR) mutation in a patient with steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis. Nephrol Dial Transplant 2005;20:336-41.
72. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996;334:878-83.
73. Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jaques J et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994;330:7-14.
74. Verani RR, Hawkins EP. Recurrent focal segmental glomerulosclerosis: a pathological study of the early lesion. Am J Nephrol 1986;6:263-70.
75. Deegens JK, Andresdottir MB, Croockewit S, Wetzels JF. Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant. Transpl Int 2004;17:151-7.
76. Cattran D, Neogi T, Sharma R, McCarthy ET, Savin VJ. Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol 2003;14:448-53.
77. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004;15:2169-77.
78. Meyner A. E pluribus unum: the riddle of focal segmental glomerulosclerosis. Semin Nephrol 2003;23:135-40.
79. Praga M, Morales E, Herrero J, Dominguez-Gil B, Alegre R, Vara J et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis 1999;33:52-8.
80. Detwiler R, Falk R, Hogan S, Jennette J. Collapsing glomerulopathy: a clinical and pathologic distinct variant of focal segmental glomerulosclerosis. Kidney Int 1994;45:1416-24.
81. Valeri A, Barisoni L, Appel G, Seigle R, D'Agati V. Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study. Kidney Int 1996;50:1734-46.
82. Kambham N, Markowitz G, Valeri A, Lin J, D'Agati V. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 2001;59:1498-509.
83. Barisoni L, Szabolcs M, Ward L, D'Agati V. Visceral epithelial cell alterations in focal segmental glomerulosclerosis. Mod Pathol 1994;7:157A.
84. Deegens JK, Dijkman B, Assmann KJ, Wetzels JF. Morphometric analysis of podocytic foot processes in primary and secondary focal and segmental glomerulosclerosis. J Am Soc Nephrol 2004;15:557A.
85. Rana K, Isbel N, Buzza M, Dagher H, Henning P, Kainer G et al. Clinical, histopathologic, and genetic studies in nine families with focal segmental glomerulosclerosis. Am J Kidney Dis 2003;41:1170-8.
86. Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004;15:722-32.
87. Aucella F, Bisceglia L, Stallone C. [A genetic viewpoint of focal glomerular sclerosis: fom genes to glomerular pathophysiology]. G Ital Nefrol 2003;20:356-67. Italian.
88. Erratum in: G Ital Nefrol 2003;20:533.
89. Pollak MR. Inherited podocytopathies: FSGS and nephrotic syndrome from a genetic viewpoint. J Am Soc Nephrol 2002;13:3016-23.
90. Korbet S, Schwartz M, Lewis EJ. The prognosis of focal segmental glomerulosclerosis of adulthood. Medicine 1986;65:304-11.
91. Rydell J, Korbet S, Borok R, Schwartz M. Focal segmental glomerulosclerosis in adults: presentation, course and response to treatment. Am J Kidney Dis 1995;25:534-42.
92. Korbet SM. Clinical picture and outcome of primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 1999;14 Suppl 3:68-73.
93. Korbet SM. Primary focal segmental glomerulosclerosis. In: Brady R, Wilcox C editors. Therapy in Nephro-logy and Hypertension: A companion to Brenner and Rector's The Kidney. Philadelphia: Saunders; 2003.p. 223-36.
94. Bazzi C, Petrini C, Rizza V, Napodano P, Paparella M, Arrigo G et al. Fractional excretion of IgG predicts renal outcome and response to therapy in primary focal segmental glomerulosclerosis: A pilot study. Am J Kidney Dis 2003;41:328-33.
95. Schwartz M, Korbet S, Rydell J, Borok R, Genchi R. Primary focal segmental glomerular sclerosis in adults: prognostic value of histologic variants. Am J Kidney Dis 1995;25:845-52.
96. Ponticelli C, Villa M, Banfi G, Cesana B, Pozzi C, Pani A et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 1999;34:618-25.
97. Praga M, Hernandez E, Montoyo C, Andres A, Ruilope LM, Rodicio JL. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992;20:240-8.
98. Crenshaw G, Bigler S, Salem M, Crook ED. Focal segmental glomerulosclerosis in African Americans: effects of steroids and angiotensin converting enzyme inhibitors. Am J Med Sci 2000;319:320-5.
99. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63.
100. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352:1252-6.
101. Keilani T, Schlueter WA, Levin ML, Batlle DC. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 1993;118:246-54.
102. de Sain-van der Velden MG, Kaysen GA, Barrett HA, Stellaard F, Gadellaa MM, Voorbij HA et al. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 1998;53:994-1001.
103. Wanner C, Rader D, Bartens W, Kramer J, Brewer HB, Schollmeyer P et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993;119:263-9.
104. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993;44:638-42.
105. Curry RC Jr, Roberts WC. Status of the coronary arteries in the nephrotic syndrome. Analysis of 20 necropsy patients aged 15 to 35 years to determine if coronary atherosclerosis is accelerated. Am J Med 1977;63:183-92.
106. Kasiske BL, Velosa JA, Halstenson CE, La Belle P, Langendorfer A, Keane WF. The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am J Kidney Dis 1990;15:8-15.
107. Spitalewitz S, Porush JG, Cattran D, Wright N. Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy. Am J Kidney Dis 1993;22:143-50.
108. Rabelink AJ, Hene RJ, Erkelens DW, Joles JA, Koomans HA. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 1988;2:1335-8.
109. Vega GL, Grundy SM. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. Kidney Int 1988;33:1160-8.
110. Thomas ME, Harris KP, Ramaswamy C, Hattersley JM, Wheeler DC, Varghese Z et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 1993;44:1124-9.
111. Olbricht CJ, Wanner C, Thiery J, Basten A. Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group. Kidney Int Suppl 1999;71:S113-6.
112. Matzkies FK, Bahner U, Teschner M, Hohage H, Heidland A, Schaefer RM. Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome. Am J Nephrol 1999;19:492-4.
113. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
114. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Tex CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622.
115. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003;14:1605-13.
116. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41:565-70.
117. Pei Y, Cattran D, Delmore T, Katz A, Lang A, Rance P. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Am J Med 1987;82:938-44.
118. Pokhariyal S, Gulati S, Prasad N, Sharma RK, Singh U, Gupta RK et al. Duration of optimal therapy for idiopathic focal segmental glomerulosclerosis. J Nephrol 2003;16:691-6.
119. Cattran D, Rao P. Long term outcome of children and adults with classic focal and segmental glomerulosclerosis. Am J Kidney Dis 1998;32:72-9.
120. Banfi G, Moriggi M, Sabadini E, Fellin G, D'Amico G, Ponticelli C. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991;36:53-9.
121. Alexopoulos E, Stangou M, Papagianni A, Pantzaki A, Papadimitriou M. Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 2000;15:1348-56.
122. Agarwal S, Dash S, Tiwari S, Bhuyan U. Idiopathic adult focal segmental glomerulosclerosis: a clinicopathological study and respons to steroids. Nephron 1993;63:168-71.
123. Nagai R, Cattran D, Pei Y. Steroid therapy and prognosis of focal segmental glomerulosclerosis in the elderly. Clin Nephrol 1994;42:18-21.
124. Cameron JS. The long term prognosis of patients with focal glomerulosclerosis. Clin Nephrol 1978;10:213-29.
125. Meyrier A, Condamin MC, Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clin Nephrol 1991;35 Suppl 1:537-42.
126. Lee H, Kim H, Kang C, Kim S, Kim M. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Clin Nephrol 1995;43:375-81.
127. Lim V, Sibley R, Spargo B. Adult lipoid nephrosis: clinicopathological correlations. Ann Intern Med 1974;81:314-20.
128. Saint-Hillier Y, Morel-Maroger L, Woodrow D, Richet G. Focal and segmental hyalinosis. Adv Nephrol Necker Hosp 1975;5:67-88.
129. Cattran D, Appel G, Hebert L, Hunsicker L, Pohl M, Hoy W et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999;56:2220-6.
130. Ponticelli C, Rizzoni G. Edefonti A, Altieri P, Rivolta E, Rinaldi S et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993;43:1377-84.
131. Maher ER, Sweny P, Chappel M, Varghese Z, Moorhead JF. Cyclosporin in the treatment of steroid-responsive and steroid-resistant nephrotic syndrome in adults. Nephrol Dial Transplant 1988;3:728-32.
132. Ittel T, Clasen W, Fuhs M, Kindler J, Mihatsch M, Sieberth H. Long-term ciclosporine A treatment in adults with minimal change nephrotic syndrome or focal segmental glomerulosclerosis. Clin Nephrol 1995;44:156-62.
133. Walker R, Kincaid-Smith P. The effect of treatment of corticosteroid-resistant idiopathic (primary) focal and segmental hyalinosis and sclerosis (focal glomerulosclerosis) with ciclosporin. Nephron 1990;54:117-21.
134. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 1993;8:1326-32.
135. Wetzels J. Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis? Neth J Med 2004;62:347-52.
136. Meyrier A, Noel L, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int 1994;45:1446-56.
137. Burgess E. Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int Suppl 1999;70:S26-32.
138. Cameron JS. Focal segmental glomerulosclerosis in adults. Nephrol Dial Transplant 2003;18 Suppl 6:45-51.
139. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1996;10:590-3.
140. Berger J, Hinglais N. Les depots intercapillaires d'IgA-IgG. J Urol Nephrol 1968;74:694-5.
141. Emancipator S. Primary and secondary forms of IgA nephritis, Schonlein-Henoch syndrome. In: Heptinstall R, editor. Pathology of the Kidney. Boston, MA: Little Brown; 1998.p.389-476.
142. Jennette JC. The immunohistology of IgA nephropathy. Am J Kidney Dis 1988;12:348-52.
143. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000;36:227-37.
144. Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000;26:354-7.
145. Barratt J, Feehally J, Smith AC. Pathogenesis of IgA nephropathy. Semin Nephrol 2004;24:197-217.
146. Roos A, Bouwman LH, Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001;167:2861-8.
147. Floege J, Feehally J. IgA nephropathy: recent developments. J Am Soc Nephrol 2000;11:2395-403.
148. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 1990;89:209-15.
149. Hogg RJ. Usual and unusual presentations of IgA nephropathy in children. Contrib Nephrol 1993;104:14-23.
150. Feith GW, Assmann KJ, Wetzels JF. Acute renal failure in patients with glomerular diseases: a consequence of tubular cell damage caused by haematuria? Neth J Med 2003;61:146-50.
151. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997;8:199-207.
152. Woo KT, Lau YK, Lee GS, Wei SS, Lim CH. Pattern of proteinuria in IgA nephritis by SDS-PAGE: clinical significance. Clin Nephrol 1991;36:6-11.
153. Alexopoulos E. Treatment of primary IgA nephropathy. Kidney Int 2004;65:341-55.
154. D'Amico G, Ragni A, Gandini E, Fellin G. Typical and atypical natural history of IgA nephropathy in adult patients. Contrib Nephrol 1993;104:6-13.
155. Scholl U, Wastl U, Risler T, Braun N, Grabensee B, Heering P et al. The "point of no return" and the rate of progression in the natural history of IgA nephritis. Clin Nephrol 1999;52:285-92.
156. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62.
157. Jafar T, Stark P, Schmid C, Landa M, Maschio G, de Jong P et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244-52.
158. K/DOQI Clinical practice Guidelines in Hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S159-75.
159. K/DOQI Clinical practice Guidelines in Hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S183-205.
160. Cattran DC, Greenwood C. Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994;23:247-54.
161. Rekola S, Bergstrand A, Bucht H. Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance. Kidney Int 1991;40:1050-4.
162. Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ. Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 1995;111:184-92.
163. Cheng IK, Fang GX, Wong MC, Ji YL, Chan KW, Yeung HW. A randomised prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology 1998;4:189-26.
164. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephroic proteinuria. Lancet 1999;354:359-64.
165. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003;14:1578-83.
166. Perico N, Remuzzi A, Sangalli F, Azzollini N, Mister M, Ruggenenti P et al. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 1998;9:2308-17.
167. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999;33:851-6.
168. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24.
169. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2003; CD003965.
170. Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S. Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron 1996;72:237-42.
171. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999;353:883-7.
172. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004;15:157-63.
173. Shoji T, Nakanishi I, Suzuki A, Hayashi T, Togawa M, Okada N et al. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 2000;35:194-201.
174. Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, Ando T, Yanase T et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis 2003;41:972-83.
175. Lai KN, Lai FM, Li PK, Vallance-Owen J. Cyclosporin treatment of IgA
176. Woo KT, Edmondson RP, Yap HK, Wu AY, Chiang GS, Lee EJ et al. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clin Nephrol 1987;27:56-64.
177. Walker RG, Yu SH, Owen JE, Kincaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol 1990;34:103-7.
178. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002;13:142-8.
179. Harmankaya O, Ozturk Y, Basturk T, Obek A, Kilicarslan I. Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria. Int Urol Nephrol 2002;33:167-71.
180. Goumenos DS, Davlouros P, El Nahas AM, Ahuja M, Shortland JR, Vlachojannis JG et al. Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study. Nephron Clin Pract 2003;93:C58-C68.
181. Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004;65:1842-9.
182. Hamazaki T, Tateno S, Shishido H. Eicosapentaenoic acid and IgA nephropathy. Lancet 1984;1:1017-8.
183. Bennett WM, Walker RG, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial. Clin Nephrol 1989;31:128-31.
184. Pettersson EE, Rekola S, Berglund L, Sundqvist KG, Angelin B, Diczfalusy U et al. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study. Clin Nephrol 1994;41:183-90.
185. Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994;331:1194-9.
186. Donadio JV Jr, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 1999;10;1772-7.
187. Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 1997;8:1739-44.
188. Lee GS, Choong HL, Chang GS, Woo KT. Three-year randomised controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment. Nephrology 1997;3:117-21.
189. Chan MK, Kwan SY, Chan KW, Yeung CK. Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. Am J Kidney Dis 1987;9:417-21.
190. Hotta O. Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy. Semin Nephrol 2004;24:244-55.
191. Xie Y, Nishi S, Ueno M, Imai N, Sakatsume M, Narita I et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 2003;63:1861-7.
192. Lai KN, Lai FM, Ho CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986;26:174-80.
193. Roccatello D, Ferro M, Cesano G, Rossi D, Berutti S, Salomone M et al. Steroid and cyclophosphamide in IgA nephropathy. Nephrol Dial Transplant 2000;15:833-5.
194. Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 2003;18:1321-9.
195. Harper L, Ferreira MA, Howie AJ, Savage CO, Richards NT, Michael J et al. Treatment of vasculitic IgA nephropathy. J Nephrol 2000;13:360-6.
196. Roccatello D, Ferro M, Coppo R, Giraudo G, Quattrocchio G, Piccoli G. Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy. Nephrol Dial Transplant 1995;10:2054-9.